Women with relapsed ovarian cancer can take part in SOLO3, a clinical study for ovarian cancer, supported by AstraZeneca, to help scientists find better treatments for this disease. This page provides information about the SOLO3 clinical trial.
A clinical study of olaparib in women who:
- Have previously been diagnosed and treated for ovarian cancer, peritoneal cancer, and/or fallopian tube cancer and their disease has come back. This is termed ‘relapsed’ or ‘recurrent’ cancer
- Have an inherited BRCA mutation
- Have completed at least two courses of platinum-based chemotherapy, and finished the last course at least six months ago. Platinum agents are carboplatin, cisplatin, and oxalaplatin
- Have a tumor that has shrunk or disappeared following their last course of platinum-based chemotherapy